

Journal of
**Family Planning &
 Reproductive Health Care**

**Presenting risk information in sexual and reproductive
 health care**

Journal:	<i>Journal of Family Planning and Reproductive Health Care</i>
Manuscript ID	jfprhc-2012-100301.R2
Article Type:	Research
Date Submitted by the Author:	n/a
Complete List of Authors:	David, Anna; University College London, Institute for Women's Health Akintomide, Hannat; Margaret Pyke Centre, CNWL Camden Provider Services – Sexual and Reproductive Health
Keywords:	epidemiology, communication of risk, clinical decision-making, informed consent, counseling, sexual and reproductive health service provision
Abstract:	<p>Objectives: Presenting risk information to patients is an important part of clinical encounters. Good risk communication improves patient satisfaction with care and their decisions. In sexual and reproductive health care, women frequently need to make decisions based on their perceived risk. Risk perception can be altered by how actual risk is presented to patients.</p> <p>Methods: Databases were searched using MeSH terms combined with a keyword search for articles relevant to sexual and reproductive health; the search was limited to English language.</p> <p>Results: Personalised risk communication where a risk score is provided, increases knowledge and slightly increases uptake of screening tests. Decision aids improve patient's knowledge of the options, create realistic expectations of their benefits and harms, reduce difficulty with decision-making and increase participation in the process. The most effective way to present risks uses a range of structured, tailored presentation styles; interactive formats are best. Framing the information improves patient understanding. Most people understand natural frequencies or event rates better than probability formats with varying denominators. Expressing changes in risk as an absolute risk reduction or relative risk reduction with baseline risk formats improves understanding. Descriptive terms such as 'low risk' or 'high risk' should be quantified as a frequency rather than a percentage. Using a consistent denominator to portray risk is recommended. Using the "number needed to treat" and visual aids puts benefits or risks into perspective. The duration of risk should be presented.</p> <p>Conclusions: Presenting risk information to patients can be optimised using a number of strategies.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

Confidential: For Review Only

Presenting risk information in sexual and reproductive health care

Anna L David¹, Hannat Akintomide²

1. Institute for Women's Health, University College London, London, WC1E 6HX, UK

2. CNWL Camden Provider Services – Sexual and Reproductive Health, Margaret Pyke Centre, London, UK

Corresponding author: Anna David, a.david@ucl.ac.uk, 07852220375
Reader and Consultant in Obstetrics and Maternal Fetal Medicine,
Institute for Women's Health,
86-96 Chenies Mews
London
WC1E 6HX

Keywords: ~~health education,~~ health education, counseling, ~~medico-legal,~~ education
~~and training,~~ sexual and reproductive health family planning-service provision,
~~epidemiology~~communication of risk, clinical decision-making, decision support
techniques, clinical decision support systems, informed consent, reproductive
medicine.

Abstract

Objectives: Presenting risk information to patients is an important part of clinical encounters. Good risk communication improves patient satisfaction with care and their decisions. In sexual and reproductive health care, women frequently need to make decisions based on their perceived risk. Risk perception can be altered by how actual risk is presented to patients.

Methods: ~~Databases were searched using MeSH terms combined with a keyword search for articles relevant to sexual and reproductive health; the search was limited to English language. We searched the literature to identify strategies to improve patient understanding of risks and decision-making with relevance to sexual and reproductive health.~~

Results: Personalised risk communication where a risk score is provided, increases knowledge and slightly increases uptake of screening tests. Decision aids improve patient's knowledge of the options, create realistic expectations of their benefits and harms, reduce difficulty with decision-making and increase participation in the process. The most effective way to present risks uses a range of structured, tailored presentation styles; interactive formats are best. Framing the information improves patient understanding. Most people understand natural frequencies or event rates better than probability formats with varying denominators. Expressing changes in risk as an absolute risk reduction or relative risk reduction with baseline risk formats improves understanding. Descriptive terms such as 'low risk' or 'high risk' should be quantified as a frequency rather than a percentage. Using a consistent denominator to portray risk is recommended. Using the "number needed to treat" and visual aids puts benefits or risks into perspective. The duration of risk should be presented.

Conclusions: Presenting risk information to patients can be optimised using a number of strategies.

Formatted: English (U.K.)

Key Message Points

- Presenting risk information to patients is an important part of clinical encounters and good risk communication improves patient satisfaction with care.
- Strategies to improve patient understanding of risks include providing personalised risks, using decision aids, presenting information in a variety of structured, tailored and/or interactive formats.
- To quantify risk, use numbers rather than words, event rates or natural frequencies, rather than probabilities or relative risk reduction, absolute risks rather than relative risks.

Introduction

Healthcare professionals often need to discuss risks with patients in sexual and reproductive health care. One suggested approach involves first describing the frequency of the risk and then the possible associated harm (1). For instance, the risk of perforation during insertion of an intrauterine device (IUD) is 0-2.3 per 1000 insertions, which is rare to uncommon, but this must be qualified by the amount of associated harm such as bowel perforation and peritonitis. Both healthcare professionals and patients have difficulty understanding risk in terms of numerical odds and probabilities (2). [The RCOG Clinical Governance Advice on Presenting Information on Risk provides general principles on how best to communicate risk in women's health](#) (3). In this paper we discuss how best to define and present descriptions of risk in clinical decision-making with patients [in sexual and reproductive health](#), using examples relevant to sexual and reproductive health care.

Methodology

We searched the Cochrane Library ([Cochrane Central Register of Controlled Trials \(CENTRAL\)](#)), HTA and the National Research Register), Cochrane Database of Systematic Reviews, the [Centre for Reviews and Dissemination](#), the Database of Abstracts of Reviews of Effects (DARE), [MEDLINE \(Ovid\)](#), Excerpta Medica dataBASE (EMBASE), [Turning Research Into Practice \(TRIP\)](#) database, National Electronic Library of Health and Medline for relevant studies and articles published between 1966 and August 2015. [The databases were searched using the relevant MeSH terms including all sub-headings \('clinical decision-making', 'decision support techniques', 'decision support systems, clinical', 'decision-making, computer-assisted', 'decision trees', 'communication', 'informed consent', 'consent forms', 'reproductive medicine' and 'health education'. This was combined with a keyword search that included 'presentation of risk', 'public perception of risk', 'communication of risk', 'consent', 'decision-aid', 'counseling', and the search was limited to English language. The following websites were also searched using the above phrases: Bandolier, MHRA, Royal College of Physicians, Royal College of Anaesthetists, Royal College of Surgeons, Royal College of Obstetricians & Gynaecologists, Department of Health, Medical Defence Union, NICE, SIGN, National Screening Committee, World Health Organisation, The Risk Information Institute, Kings Fund, Royal Society, Research Findings Register, The National Health and Medical Research Council of Australia, the International Patient Decision Aid Standards Collaboration, The Institute of Risk Management. We included trials, qualitative studies, systematic reviews and reviews addressing decision-making, decision-aids,](#)

counselling, risk presentation, communication or its public perception and consent, in relation to sexual and reproductive health.

Databases were searched using the relevant MeSH terms, including all subheadings, combined with a keyword search. We used the following search words: 'presentation of risk', 'public perception of risk', 'communication of risk', 'consent', 'decision making'; the search was limited to English language.

What is risk?

A risk is the likelihood (or probability) that harm will occur from a particular hazard (4). Patients may be concerned with broader qualitative attributes, such as the origin of the risk (natural or technological), whether a risk is imposed or temporary and the power that they have to control the risk (5). Many times in reproductive healthcare there are hazards associated with a particular decision. For example, there are risks of pelvic inflammatory disease with an IUD,, a probability of up to 9 in 100 of pregnancy with typical use of combined oral contraception (6) or a consequence that well over half of progestogen implant users experience a change in menstrual bleeding pattern (7). Patients will generally take risks if they perceive that there is an advantage or benefit. Normally, the benefits should outweigh the risks by a significant margin. There is no such thing as a zero risk (8)(9) and patients should be made aware that there is no medicine or drug without a possible risk or side effect, including medicines used for contraception.

Risk perception is subjective (10). Patients tend to act on the basis of their perception of the risk rather than the on 'actual' risk presented to them (11). Their estimates of risk may differ from those of the healthcare professional who counsels them (12)(2)(13). Other factors may play a role. For example uptake of genetic testing in prenatal care was strongly predicted by women's general attitude to genetic testing, independent of risk perception (14). Risks may be perceived as far less tolerable if the treatment or intervention is voluntary, the technology is unfamiliar or has no benefit for the patient.

The importance of good risk communication

Good communication helps to build trusting relationships between patients and professionals, leads to greater satisfaction on both sides (4), with less fear of treatments (15), helps people to take more responsibility for their own health, reduces medical errors and mishaps and even malpractice claims (16)(10).

1
2
3
4
5
6 Healthcare professionals tend to consider risk as the mathematical probability of
7 something happening within a whole population group (for example, the chance of an
8 ectopic pregnancy in women using an IUD), which is supported by statistical
9 information (1). This way of assessing risk is important, but it is objective,
10 impersonal and deals with populations rather than individuals. Patients on the other
11 hand, use an everyday concept of risk that is bound up in the individual's concerns,
12 anxieties and fears about the present and the future ("What is *my* risk of having an
13 ectopic pregnancy while using an IUD?" for example). Understanding the uncertainty
14 about a treatment is thought to be a critical element of an informed decision and
15 should be communicated effectively to patients (17)(18). At the same time,
16 healthcare professional should make an assessment of the patient's mental capacity
17 to understand the information given, considering this in light of the Mental Capacity
18 Act 2005. Healthcare professionals have traditionally communicated risk poorly (19),
19 but developments such as patient decision aids can improve risk communication
20 (20).
21
22
23
24
25
26
27

28 **Legal aspects of risk pertaining to patient consent**

29 The legal position on whether or not a doctor or other healthcare professional is
30 negligent in failing to mention a risk to a surgical patient was decided in the UK in the
31 case of Sidaway (21). The more recent Montgomery vs Lanarkshire judgment (22)
32 highlights the importance of an individual approach to advising a patient about a risk.
33 When discussing the benefits and risks of various treatment options with patients, the
34 new ruling requires doctors to consider whether "a reasonable person in the patient's
35 position would be likely to attach significance to the risk, or the doctor is or should
36 reasonably be aware that the particular patient would be likely to attach significance
37 to it" (22). Rather than a radical change in medical practice, the judgement has been
38 considered to bring the law in line with current ethical guidance for UK doctors, as
39 stated in the GMC guidance on consent (23). It is therefore advisable to inform the
40 patient of any 'material' or 'significant' risks of the proposed treatment, any
41 alternatives to it and the risks incurred by doing nothing. A Court of Appeal judgment
42 stated that it will normally be the responsibility of the doctor to inform a patient of 'a
43 significant risk which would affect the judgment of a reasonable patient' (Pearce v
44 United Bristol Healthcare NHS Trust (1998) 48 BMLR 118 (CA) (24). It is appropriate
45 to warn of a relatively rare risk for an elective procedure, for example pregnancy
46 following laparoscopic sterilization, since this has a huge impact on the patient if it
47 occurs.
48
49
50
51
52
53
54
55
56
57
58
59
60

How to communicate risks

Risks in sexual and reproductive healthcare are personal and rich in uncertainty and there are no clear best practices for presenting information about uncertainty (17). Risk communication can be improved however, by using certain strategies described below.

1. Firstly, personalised risk communication tailors information to an individual's risk status. For example, current evidence suggests a risk of weight gain with Depo Provera[®] injection use compared to the oral contraception or no hormonal contraceptive method, and more so if the user is already overweight. This risk can be personalised eg. by telling a woman with a body mass index (BMI) of 32 that the average increase in weight over 18 months after starting Depo Provera[®] is 9.4kg compared to 0.2kg if she took oral contraception and 3.1kg if she did not use hormonal contraception (25). Personalising risk communication enhances informed decision-making (26). A Cochrane Systematic Review found that for individuals undergoing screening procedures, interventions with a 'personalised risk communication element', enhance informed decision making (26). Overall 45.2% (592/1309) of participants who received personalised risk information made informed choices, compared to 20.2% (229/1135) of participants who received generic risk information (Odds ratios for random effects 3.65 (95% CI 2.13 to 6.23). Personalized risk communication does not significantly increase the uptake of such screening tests.

2. Using a range of presentation styles and risk communication tools is the most effective way to give information about risks to patients (27). An RCT of women's understanding of the effectiveness of contraceptive methods found that tables with categories such as "more" or "less effective" communicated relative effectiveness better than numeric tables. However, women grossly overestimated the risk of pregnancy unless they were shown tables with numbers, so a combination of both methods was best (28). Graphically presenting risk information in addition helped general practitioners to build a relationship with women, and allowed them to convey absolute and relative risks quickly without having to explain these concepts (29). A specifically designed tool, the Paling palette (Risk Communication Institute, http://www.riskcomm.com/paling_palettes.htm) can display most medical risks with a probability of higher than 1/1000. The chart shows 1000 people, with the number

1
2
3
4
5
6 experiencing a particular effect coloured in (Figure 1). An alternative system uses
7 icon arrays (www.iconarray.com), a matrix of usually 100 to 1000 icons to represent
8 an at-risk population, simultaneously displaying both the number of expected events
9 and the number of expected non-events.
10

11
12
13 3. Framing health information as negative or positive can affect patient
14 understanding of risk (30)(31). For example, the chances of combined oral
15 contraception can be presented: in a good user failing (less than 1 in 100, negative
16 framing) versus the chances of successful contraception (over 99 in 100, positive
17 framing). People receiving information framed as a positive or a gain, are more
18 confident of a treatment than those receiving information presented as a negative or
19 loss. Since framing of information can have such a profound effect on patient
20 perception of risk, framing information in a variety of ways is recommended to avoid
21 misunderstanding (32). For example, a patient may be told that there is a 1 in 10
22 chance that she will have a pregnancy in the first year of using a diaphragm, so this
23 is a 9 out of 10 chance that she will not conceive in the first year (typical risk of
24 contraceptive failure with a diaphragm is 16%).
25
26
27
28
29

30
31 4. The duration of the risk should also be discussed with the patient at the same time
32 as discussing the amount of risk (33). For example the risk of pelvic inflammatory
33 disease after insertion of an IUD among 22,908 IUD insertions and during 51,399
34 woman-years of follow-up was 1.6 cases per 1000 woman-years of use on average,
35 but after adjustment for confounding factors, PID risk was more than six times higher
36 during the 20 days after insertion than during later times (unadjusted rates, 9.7 vs 1.4
37 per 1000 woman-years, respectively); the risk was low and constant for up to eight
38 years of follow-up (34).
39
40
41
42

43 **Aiding Decision-making**

44 Decision aids such as pamphlets or videos prepare patients to participate in
45 decisions by providing information about treatment or screening options and their
46 associated outcomes. When compared with usual care, decision aids performed
47 better in terms of greater knowledge, more realistic expectations, lower decisional
48 conflict and an increased proportion of people participating in decision-making (20).
49 More detailed decision aids such as booklets or computer based programs are better
50 than simpler ones and significantly improve knowledge, create more realistic
51 expectations and greater agreement between values and choice. A decision aid to
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 choose pregnancy termination methods for example, improved knowledge and
7 reduced risk-perception scores about both methods compared to usual counseling
8 (35). In general, structured, tailored and/or interactive communication tools are more
9 effective at increasing patient's understanding of evidence (36). For contraceptive
10 methods, a recent systematic review found that a range of educational interventions
11 can increase knowledge (37). Further research is needed however to determine what
12 aspects of educational interventions are most effective, whether an educator is
13 needed and how education may impact behaviours.
14
15
16
17
18

19 **Presenting Numerical Risk Information for Patients**

20 The format in which written and verbal information on probability is presented affects
21 patient understanding of risk. Patients have a more accurate perception of risk if the
22 information is presented as numbers rather than words (36). Presenting natural
23 frequencies, which is a joint frequency of two events, such as the number of patients
24 with a disease and who have a positive test result (38) may also be of benefit.
25 A change in risk is better understood if absolute risk reduction, or a relative risk
26 reduction with the baseline risk format for the disease, is used (36). For example,
27 there is up to a 30% (30 out of 100) chance of pregnancy when a woman has
28 unprotected sex during her fertile period. Typical failure of condoms to prevent
29 pregnancy is 10-15% (10-15 per 100 women). By using the IUD for emergency
30 contraception this risk of pregnancy is reduced to less than 1% (less than 1 in 100
31 women will get pregnant). The absolute pregnancy risk reduction is 29% with IUD
32 use, greater than with condom use. Further worked examples for calculating risk
33 reduction are available (39). Descriptive terms such as 'very low risk' or 'high risk'
34 may be used, but they should be qualified by giving a figure, such as a frequency
35 since they can reflect the speaker's perspective and not the patient's view (40).
36 European Union (EU) guidelines recommend verbal descriptors of risk (9). From a
37 regulatory perspective for patient information leaflets, the emphasis is to express risk
38 as a statistical probability, for example a verbal descriptor such as 'very rare'
39 corresponds to 'up to 0.01%' (less than 1/10 000). However, research into what
40 individuals understand by terms such as 'very rare' or 'common' suggests that the
41 current EU guidelines on verbal descriptors are not correctly matched with statistical
42 probabilities (41)(42). The public equate the verbal descriptors (very rare, common,
43 and so on) to risks that are substantially higher than those defined in regulatory
44 documents. The current EU guidelines are provided in Table 1 (9).
45 Percentages are an abstract way of portraying risk (for example 5%), whereas the
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 actual number of people who could be affected is more vivid to some patients (for
7 example, five of every 100 people). When quantifying risks therefore, it is
8 recommended to use frequencies rather than percentages to portray risk (41), and to
9 help compare between risks, use a consistent denominator (42). Example 1 below
10 uses a consistent denominator to compare venous thromboembolism risks. Another
11 example using a constant denominator considers contraceptive efficacy, stating that
12 in a year of use, 99 out of 100 women will not get pregnant with an IUD, whereas
13 only 85 out of 100 women will not get pregnant with typical use of a male condom.
14
15
16

17
18 Using relative risks alone to compare different options can be misleading (41) as was
19 demonstrated in the 1995 'pill scare'. Epidemiologists reported that use of third-
20 generation oral contraceptives doubled the risk of thromboembolism compared with
21 use of second generation oral contraceptives (43). The initial reports did not mention
22 that the absolute risks were low: 1/3000 compared with 1/6000, that the background
23 risk in non-users was 1/20 000 or that the increased risk of death was around 1/1
24 000 000. The risk was not put into context and media and public panic ensued (44).
25 Evidence suggests that presenting the risk of thrombosis complications in terms of
26 incidence rather than relative risk may improve communication of side effects during
27 counselling for combined hormonal contraception initiation (Machado et al. 2015).
28 Over the last decade there has however been little improvement in the reporting of
29 absolute risks (45). For many observational studies and meta-analyses, absolute
30 risks cannot be reported easily or meaningfully. Wherever possible absolute risks
31 should be stated, since using absolute data allows the consumer to more easily
32 compare different risks (41).
33
34
35
36
37
38
39

40 Examples of communicating risks in sexual and reproductive healthcare are listed
41 below.
42
43

44 **Example 1: A woman asks you what her risk is of having venous**
45 **thromboembolism (VTE) while using the combined pill.**

46 The risk of VTE (deep venous thrombosis and pulmonary embolism) in women who
47 are not using the combined contraceptive pill is 2-5/10,000 woman-years (46). This
48 means that in 10,000 women not using the pill over a one-year period up to 5 may
49 have VTE (hence it is "rare"). This doubles to 5-12/10,000 woman years, which is still
50 rare to uncommon, in women who are using combined hormonal contraception
51 (47)(48). In pregnancy and the immediate postpartum, the risk of VTE is much
52 higher: 29/10000 woman years and over 10 times higher postpartum - 300-
53
54
55
56
57
58
59
60

1
2
3
4
5
6 400/10000 woman years. VTE is therefore rare in women who use the combined pill.
7 Women are at a far greater risk of VTE postpartum or during pregnancy than while
8 taking the combined pill as shown in Table 2.
9

10
11 **Example 2: A woman is interested in having intrauterine contraception but has**
12 **heard intrauterine devices (IUDs) are associated with pelvic infection. She asks**
13 **what her risk is of having a pelvic infection if she chooses an IUD.**
14

15 The risk of a pelvic infection while using intrauterine contraception is generally low
16 (49), but is increased where there is a sexually transmitted infection (STI) and in the
17 first 3 weeks after IUD insertion. The most comprehensive review to date of
18 insertions and IUD use suggests a risk of up to 16/10,000 woman years (34). Hence
19 pelvic infection after IUD insertion or with IUD use is uncommon. Also, pelvic
20 infection has not been found to be higher in women using IUDs compared to women
21 who are using other methods of contraception such as progestogen-only injectables
22 (50) or no contraception (51). By preventing STIs, the risk of pelvic infection with IUD
23 is further reduced. The patient should be offered an STI screen before her IUD
24 insertion and should practise safer sex to reduce her risk of pelvic infection with the
25 IUD (52).
26
27
28
29
30
31


32 **Example 3: You offer a woman with post-coital bleeding (PCB) a chlamydia test**
33 **but she declines. Her last STI screen, 6 months ago, was negative and she has**
34 **not changed partner since. Her partner has never screened for STIs before, but**
35 **she believes he has no infection as her own results have been negative. What**
36 **will your advice be?**
37
38

39
40 her own negative test results may suggest, but cannot guarantee, that her partner
41 does not have an infection. Most currently used STI test kits have a sensitivity and
42 specificity of over 97%, so the test will miss 3 in 100 (or 1 in 30) infections. The
43 efficiency of a test depends on the test's ability to give a positive result when there is
44 an infection (sensitivity) and its ability to give a negative result when there is no
45 infection (specificity). Contaminants and hormonal factors may affect a test result;
46 hence no test is 100% (53). It is therefore good practice to repeat some tests when
47 indicated, even if the patient may have done the test previously. This patient has
48 post-coital bleeding and a chlamydia test is clinically indicated. You would therefore
49 recommend a repeat chlamydia test, and an STI screen for her partner.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions

Presenting information about risk in a way that facilitates patient understanding improves decision-making and patient satisfaction with care. Presenting risk in a personalised way, using decision aids or interactive methods, presenting information in a variety of formats and framing the risk in both a negative and a positive way all improve risk communication. Patients have a more accurate perception of risk if information on probability is described in numbers rather than words. Most people understand natural frequencies or event rates better than probability formats with varying denominators.



Acknowledgments:

ALD receives funding at UCLH/UCL via the Department of Health's NIHR Biomedical Research Centres funding scheme. We thank Dr Jayne Kavanagh for her helpful advice during writing of this work.

Table 1. Risk table (modified from (54))

Verbal description ^a	Risk	Risk description ^b
Very common	1/1 to 1/10	A person in family
Common	1/10 to 1/100	A person in street
Uncommon	1/100 to 1/1000	A person in village
Rare	1/1000 to 1/10 000	A person in small town
Very rare	Less than 1/10 000	A person in large town


a EU-assigned frequency

b Unit in which one adverse event would be expected

Table 2: Risk of venous thromboembolism (VTE) associated with non-use, combined hormonal contraception (CHC) use over the course of 1 year (55).

	Risk of VTE per 10,000 healthy women
Non contraceptive users and not pregnant	2
CHC containing ethinylestradiol plus levonorgestrel, norgestimate or norethisterone	5-7
CHC containing etonogestrel (ring) and norelgestromin (patch)	6-12
CHC containing ethinylestradiol plus gestodene, desogestrel, drospirenone	9-12
Pregnancy	29
Immediately post partum	300-400

Figure 1: A graphic display to compare the effectiveness of different types of emergency contraception. Developed using data from (56)(57).



References

1. Herxheimer A. Communicating with patients about harms and risks. *PLoS Med*. 2005 Feb;2(2):e42.
2. Lloyd A, Hayes P, Bell PR, Naylor AR. The role of risk and benefit perception in informed consent for surgery. *Med Decis Mak*. 2001;21:141–9.
3. Royal College of Obstetricians and Gynaecologists. [Clinical Governance Advice No. 7](#). Presenting Information On Risk. 2008.
4. Lloyd AJ. The extent of patients' understanding of the risk of treatments The extent of patients' understanding of the risk of treatments. *Qual Saf Heal Care*. 2001;(November 2006):13–8.
5. Calman KC. *BMJ Cancer : Science And Society And The Communication Of Risk*. *BMJ Br Med J*. 2014;313(7060):799–802.
6. Trussell J. Contraceptive failure in the United States. *Contraception*. 2011;83:397–404.
7. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. *Eur J Contracept Reprod Health Care*. 2008;13 Suppl 1:13–28.
8. Fischhoff B, Slovic P, Lichtenstein S, Read S, Combs B. How safe is safe enough? A psychometric study of attitudes towards technological risks and benefits. *Policy Sci*. 1978;9:127–52.
9. Slovic P. Perception of Risk. *Science (80-)*. 2007;236(4799):280–5.
10. Levinson W, Roter DL, Mullooly JP, Dull VT, Frankel RM. Physician-patient communication. The relationship with malpractice claims among primary care physicians and surgeons. *JAMA*. 1997;277:553–9.
11. Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Meta-analysis of the relationship between risk perception and health behavior: The example of vaccination. *Heal Psychol*. 2007 Mar;26(2):136–45.
12. Ellis ADA, Hopkin JM, Leitch AG, Crofton J, The S, Medical B, et al. 'Doctors' Orders ": Controlled Trial Of Supplementary , Written Information For Patients. *BMJ Br Med J*. 1979;1(6161):456.
13. US National Research Council. *Improving Risk Communication: Report of the Committee on Risk Perception and Communication*. 1989.
14. Barnoy S, Zelikaman L, Bar-Tal Y. To take or not to take genetic carrier tests: personal characteristics associated with taking recommended and nonrecommended tests. *Genet Test Mol Biomarkers*. 2009;13(4):453–8.
15. Stewart MA. Effective Physician-Patient Communication and Health Outcomes: A Review. *Can Med Assoc J*. 1995;152(9):1423–33.
16. Gordon-Lubitz RJ. Risk Communication : Problems of Presentation. *JAMA*. 2003;289(1):10–1.
17. Politi MC, Han PKJ, Col NF. Eisenberg Center 2006 White Paper Series: Communicating the Uncertainty of Harms and Benefits of Medical Interventions. *Med Decis Mak*. 2007;
18. Volk RJ, Llewellyn-Thomas H, Stacey D, Elwyn G. Ten years of the International Patient Decision Aid Standards Collaboration: evolution of the core dimensions for assessing the quality of patient decision aids. *BMC Med Inform Decis Mak*. 2013;13 Suppl 2:S1.
19. Braddock CH, Edwards KA, Hasenberg NM, Laidley TL, Levinson W. Informed

- 1
2
3
4
5
6 decision making in outpatient practice. *J Am Med Assoc.* 1999;282:2313–20.
- 7 20. O'Connor A, Bennett C. Decision aids for people facing health treatment or
8 screening decisions. *Cochrane Database Syst Rev.* 2009;(1).
- 9 21. Wells WT. The Sidaway case. *Lancet.* 1985;1:709.
- 10 22. United Kingdom Supreme Court. *Montgomery v Lanarkshire Health Board*
11 UKSC 11. 2015.
- 12 23. General Medical Council. *Consent : patients and doctors making decisions*
13 *together.* 2009.
- 14 24. Dennehy L, White S. Consent, assent, and the importance of risk stratification.
15 *Br J Anaesth.* 2012 Jul;109(1):40–6.
- 16 25. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight
17 gain in obese and nonobese adolescent girls initiating depot
18 medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive
19 method. *Arch Pediatr Adolesc Med.* 2006;160:40–5.
- 20 26. Edwards AGK, Naik G, Ahmed H, Elwyn GJ, Pickles T, Hood K, et al.
21 Personalised risk communication for informed decision making about taking
22 screening tests. *Cochrane database Syst Rev.* 2013 Jan;2:CD001865.
- 23 27. Edwards A, Elwyn G, Gwyn R. General practice registrar responses to the use
24 of different risk communication tools in simulated consultations : a focus group
25 study. *BMJ Br Med J.* 1999;319(September):749–52.
- 26 28. Steiner MJ, Dalebout S, Condon S, Dominik R, Trussell J. Understanding risk:
27 A randomized controlled trial of communicating contraceptive effectiveness.
28 *Obstet Gynecol.* 2003;102:709–17.
- 29 29. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into
30 meaningful pictures. *BMJ Br Med J.* 2002;324:827–30.
- 31 30. Paling J. Strategies to help patients understand risks. *BMJ Br Med J.*
32 2003;745–8.
- 33 31. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing
34 effect of relative and absolute risk. *J Gen Intern Med.* 1993;8:543–8.
- 35 32. O'Doherty K, Suthers GK. Risky communication: pitfalls in counseling about
36 risk, and how to avoid them. *J Genet Couns.* 2007 Aug;16(4):409–17.
- 37 33. Committee on Safety of Medicines Working Group on Patient Information.
38 *Always Read the Leaflet. Getting the best information with every medicine.*
39 2005.
- 40 34. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices
41 and pelvic inflammatory disease: an international perspective. *Lancet.* 1992.
- 42 35. Wong SSM, Thornton JG, Gbolade B, Bekker HL. A randomised controlled
43 trial of a decision-aid leaflet to facilitate women's choice between pregnancy
44 termination methods. *BJOG.* 2006 Jun;113(6):688–94.
- 45 36. Trevena LJ, Davey HM, Barratt A, Butow P, Caldwell P. A systematic review
46 on communicating with patients about evidence. *Journal of Evaluation in*
47 *Clinical Practice.* 2006. p. 13–23.
- 48 37. Pazol K, Zapata LB, Tregear SJ, Mautone-Smith N, Gavin LE. Impact of
49 Contraceptive Education on Contraceptive Knowledge and Decision Making.
50 *Am J Prev Med.* Elsevier; 2015;49(2):S46–56.
- 51 38. Gigerenzer G. What are natural frequencies? *BMJ Br Med J.* 2011
52 Jan;343:d6386.
- 53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
39. Barratt A, Wyer PC, Hatala R, McGinn T, Dans AL, Keitz S, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. *CMAJ*. 2004 Aug 17;171(4):353–8.
40. Merz JONF, Druzdzel MJ, Mazur DJ. Verbal Expressions of Probability in Informed Consent Litigation. *Med Decis Mak*. 1991;11:273–81.
41. Australian Government National Health and Medical Research Council. MAKING DECISIONS ABOUT TESTS AND TREATMENTS : Principles for better communication between healthcare consumers and healthcare professionals. 2005.
42. Grimes DA, Snively GR. Patients' understanding of medical risks: Implications for genetic counseling. *Obstet Gynecol*. 1999;93:910–4.
43. Wood R, Botting B, Dunnell K. Trends in conceptions before and after the 1995 pill scare. *Popul Trends*. 1997;5–12.
44. Mills A. Avoiding problems in clinical practice after the pill scare. *Hum Reprod Update*. 1999;5(6):639–53.
45. Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. *BMJ Br Med J*. 2006;333:1248.
46. European Medicines Agency. Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – CHMP endorses PRAC recommendation. 2013.
47. Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. *Thromb Res*. 2011;127.
48. Reid R, Leyland N, Wolfman W, Allaire C, Awadalla A, Best C, et al. SOGC clinical practice guidelines: Oral contraceptives and the risk of venous thromboembolism: an update: no. 252, December 2010. *Int J Gynaecol Obstet*. 2011;112:252–6.
49. O'Brien PA, Marfleet C. Frameless versus classical intrauterine device for contraception. *Cochrane Database Syst Rev*. 2005;CD003282.
50. Hofmeyr GJ, Singata M. Copper containing intra-uterine devices versus depot progestogens for contraception. *Cochrane Database of Systematic Reviews*. 2008.
51. Paladine HL, Blenning CE, Judkins DZ, Mittal S. Clinical inquiries. What are contraindications to IUDs? *J Fam Pract*. 2006;55:726–9.
52. Clinical Effectiveness Unit. Faculty of Sexual & Reproductive Healthcare Clinical Guidance Intrauterine Contraception. 2007.
53. British Association for Sexual Health and HIV. Chlamydia trachomatis UK Testing Guidelines. 2006.
54. Calman KC, Royston G. Risk language and dialects. *BMJ Br Med J*. 1992;(January):935–46.
55. Faculty of Sexual and Reproductive Healthcare. The FSRH statement in response to the Combined Pill Communication from the Medicines and Healthcare products Regulatory Agency (MHRA). 2014.
56. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. *Lancet*. 2010;375:555–62.
57. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

years of experience. Hum Reprod. 2012;27:1994–2000.

Confidential: For Review

